Molnupiravir

• Description:

  Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

• Product Name Alternative:

  EIDD-2801; MK-4482

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Influenza Virus; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/eidd-2801.html

• Purity:

  99.94

• Solubility:

  DMSO : 50 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C)C)=O)O1)C=C2)NC2=NO

• Molecular Formula:

  C13H19N3O7

• Molecular Weight:

  329.31

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11 (515) . pii: eaax5866.|[2]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [2492423-29-5]